Cargando…

Effects of nebivolol versus other antihypertensive drugs on the endothelial dysfunction in patients with essential hypertension

We aim to determine whether nebivolol has a better effect on endothelial dysfunction compared with other β-blockers or other classes of antihypertensive drugs. Searches of the PubMed, Embase etc. were performed to analyze all the randomized controlled trials using nebivolol to treat essential hypert...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Bingwei, Zhang, Qiuju, Zhang, Honggang, Wang, Chunxiao, Xiu, Ruijuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201558/
https://www.ncbi.nlm.nih.gov/pubmed/32342981
http://dx.doi.org/10.1042/BSR20200436
_version_ 1783529558967844864
author Li, Bingwei
Zhang, Qiuju
Zhang, Honggang
Wang, Chunxiao
Xiu, Ruijuan
author_facet Li, Bingwei
Zhang, Qiuju
Zhang, Honggang
Wang, Chunxiao
Xiu, Ruijuan
author_sort Li, Bingwei
collection PubMed
description We aim to determine whether nebivolol has a better effect on endothelial dysfunction compared with other β-blockers or other classes of antihypertensive drugs. Searches of the PubMed, Embase etc. were performed to analyze all the randomized controlled trials using nebivolol to treat essential hypertension. The primary end points included a measurement of peripheral endothelial function by brachial flow mediated vasodilatation (FMD) or forearm blood flow (FBF). A random-effect model was used to perform the meta-analysis when the studies showed significant heterogeneity, otherwise a descriptive analysis was conducted. Ten studies (689 patients) were included in qualitative analysis, four of which were included in quantitative synthesis. Meta-analysis showed that the changed FMD value before and after treatment with nebivolol was not statistically different from those treated with other β-blockers [mean difference = 1.12, 95% confidence interval (CI): −0.56, 2.81, P=0.19]. Descriptive analysis indicated that nebivolol did not have a better endothelium-protective effect than other classes of antihypertensive drugs including olmesartan and perindopril. Nebivolol is not a unique endothelial function-protective agent distinguished from other β-blockers or other classes of antihypertensive drugs. Reversal of endothelial dysfunction is a key point in the prevention and therapy of essential hypertension.
format Online
Article
Text
id pubmed-7201558
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Portland Press Ltd.
record_format MEDLINE/PubMed
spelling pubmed-72015582020-06-10 Effects of nebivolol versus other antihypertensive drugs on the endothelial dysfunction in patients with essential hypertension Li, Bingwei Zhang, Qiuju Zhang, Honggang Wang, Chunxiao Xiu, Ruijuan Biosci Rep Cardiovascular System & Vascular Biology We aim to determine whether nebivolol has a better effect on endothelial dysfunction compared with other β-blockers or other classes of antihypertensive drugs. Searches of the PubMed, Embase etc. were performed to analyze all the randomized controlled trials using nebivolol to treat essential hypertension. The primary end points included a measurement of peripheral endothelial function by brachial flow mediated vasodilatation (FMD) or forearm blood flow (FBF). A random-effect model was used to perform the meta-analysis when the studies showed significant heterogeneity, otherwise a descriptive analysis was conducted. Ten studies (689 patients) were included in qualitative analysis, four of which were included in quantitative synthesis. Meta-analysis showed that the changed FMD value before and after treatment with nebivolol was not statistically different from those treated with other β-blockers [mean difference = 1.12, 95% confidence interval (CI): −0.56, 2.81, P=0.19]. Descriptive analysis indicated that nebivolol did not have a better endothelium-protective effect than other classes of antihypertensive drugs including olmesartan and perindopril. Nebivolol is not a unique endothelial function-protective agent distinguished from other β-blockers or other classes of antihypertensive drugs. Reversal of endothelial dysfunction is a key point in the prevention and therapy of essential hypertension. Portland Press Ltd. 2020-05-05 /pmc/articles/PMC7201558/ /pubmed/32342981 http://dx.doi.org/10.1042/BSR20200436 Text en © 2020 The Author(s). https://creativecommons.org/licenses/by/4.0/ This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).
spellingShingle Cardiovascular System & Vascular Biology
Li, Bingwei
Zhang, Qiuju
Zhang, Honggang
Wang, Chunxiao
Xiu, Ruijuan
Effects of nebivolol versus other antihypertensive drugs on the endothelial dysfunction in patients with essential hypertension
title Effects of nebivolol versus other antihypertensive drugs on the endothelial dysfunction in patients with essential hypertension
title_full Effects of nebivolol versus other antihypertensive drugs on the endothelial dysfunction in patients with essential hypertension
title_fullStr Effects of nebivolol versus other antihypertensive drugs on the endothelial dysfunction in patients with essential hypertension
title_full_unstemmed Effects of nebivolol versus other antihypertensive drugs on the endothelial dysfunction in patients with essential hypertension
title_short Effects of nebivolol versus other antihypertensive drugs on the endothelial dysfunction in patients with essential hypertension
title_sort effects of nebivolol versus other antihypertensive drugs on the endothelial dysfunction in patients with essential hypertension
topic Cardiovascular System & Vascular Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201558/
https://www.ncbi.nlm.nih.gov/pubmed/32342981
http://dx.doi.org/10.1042/BSR20200436
work_keys_str_mv AT libingwei effectsofnebivololversusotherantihypertensivedrugsontheendothelialdysfunctioninpatientswithessentialhypertension
AT zhangqiuju effectsofnebivololversusotherantihypertensivedrugsontheendothelialdysfunctioninpatientswithessentialhypertension
AT zhanghonggang effectsofnebivololversusotherantihypertensivedrugsontheendothelialdysfunctioninpatientswithessentialhypertension
AT wangchunxiao effectsofnebivololversusotherantihypertensivedrugsontheendothelialdysfunctioninpatientswithessentialhypertension
AT xiuruijuan effectsofnebivololversusotherantihypertensivedrugsontheendothelialdysfunctioninpatientswithessentialhypertension